Cancer BiologybioRxiv
RAS activation via CRLF2 signaling is a widespread mechanism in Down syndrome acute lymphoblastic leukemia regardless of RAS mutations
D. Koschut, D. Ray, Z. Li…·D. Nizetic
This study shows that RAS activation via CRLF2 signaling is common in DS-ALL regardless of RAS mutations and is predictive of poor outcomes.
DOI 10.1038/s41388-020-01567-7